Long-term reproductive endocrine health in young women with epilepsy during puberty

Neurology

Volumn 62, Issue 3, 2004, Pages 445-450

  Mikkonen, K ^a   Vainionpaa L K ^a   Pakarinen, A J ^a   Knip, M ^b   Jarvela I Y ^a   Tapanainen, J S ^a   Isojarvi J I ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; OXCARBAZEPINE; SEX HORMONE; TESTOSTERONE; VALPROIC ACID;

ADOLESCENT; ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; EPILEPSY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MONOTHERAPY; OUTCOMES RESEARCH; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PUBERTY; REPRODUCTIVE HEALTH; SEX HORMONE BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

EID: 1042299824     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000106942.35533.62     Document Type: Article

References (31)

1. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
2. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997;20:519-526.
3. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
4. Rättyä J, Pakarinen AJ, Knip M, Repo-Outakoski M, Myllylä VV, Isojärvi JI. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001;57:440-444.
5. Bauer J, Isojärvi JI, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2002;73:121-125.
6. Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002;52:704-711.
7. Isojärvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290-296.
8. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
9. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-1006.
10. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
11. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995;36:676-681.
12. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18: 401-410.
13. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352: 1970-1973.
14. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-450.
15. Rättyä J, Vainionpää L, Knip M, Lanning P, Isojärvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-593.
16. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
17. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179.
18. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford: Stanford University Press, 1959.
19. Homburg R. Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996;11:29-39.
20. Keränen T, Jolkkonen J, Klosterskov Jensen P. Single-dose kinetics of oxcarbazepine after treatment with ciometidine or erythromycin. Epilepsia 1990;31(suppl 5):A641. Abstract.
21. Fraser AD, MacNeil W, Isner AF, Camfield PR. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther Drug Monit 1995;17:174-178.
22. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-582.
23. Venturoli S, Porcu E, Fabbri R, et al. Menstrual irregularities in adolescents: hormonal pattern and ovarian morphology. Horm Res 1986;24: 269-279.
24. Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137-141.
25. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
26. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Boston: Blackwell, 1992.
27. Legro RS. Polycystic ovary syndrome: the new millenium. Mol Cell Endocrinol 2001;184:87-93.
28. Tauboll E, Isojärvi JI, Harbo HF, Pakarinen AJ, Gjerstad L. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure 1999;8:490-493.
29. O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-330.
30. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 1994;330:460-465.
31. Hopkinson ZE, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998; 317:329-332.